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Edited by Judit OvadiAbstract The catalytic properties of the type II phosphoinosi-
tide 5-phosphatases of Lowe’s oculocerebrorenal syndrome,
INPP5B, Synaptojanin1, Synaptojanin2 and SKIP were analy-
sed with respect to their substrate speciﬁcity and enzymological
properties. Our data reveal that all phosphatases have unique
substrate speciﬁcities as judged by their corresponding KM and
VMax values. They also possessed an exclusive sensitivity towards
fatty acid composition, head group phosphorylation and micellar
presentation. Thus, the biological function of these enzymes will
not just be determined by their corresponding regulatory
domains, but will be distinctly inﬂuenced by their catalytic
properties as well. This suggests that the phosphatase domains
fulﬁl a unique catalytic function that cannot be fully compen-
sated by other phosphatases.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Phosphoinositide (PI) phosphatases can be classiﬁed accord-
ing to their sequence homology in two categories; the CX5R
phosphatases, which share homology to and are part of the large
tyrosine phosphatase family, and the type II phosphatases that
form a distinct small family on their own [1]. Based on their
domain structure, type II phosphatases containing an N-termi-
nal SAC1, an C-terminal BCR-GAP and an N-terminal SH2 or
proline rich domain have been classiﬁed as SAC domain* Corresponding author. Fax: +44-20-7594-5207.
E-mail address: r.woscholski@imperial.ac.uk (R. Woscholski).
Abbreviations: GIP, GAP domain containing inositol phosphatase;
OCRL, Lowe’s oculocerebrorenal syndrome; OG, octylglycoside; PI,
phosphoinositide; PtdIns, phosphatidylinositol; PtdIns-3,4,5-P3dC16,
L-a-D-myo-phosphatidylinositol 3,4,5-triphosphate 3-O-phospho
linked, D(+)-sn-1,2-di-O-hexadecanoylglyceryl; SCIP, SAC domain
containing inositol phosphatase; SKIP, skeletal muscle and kidney
enriched inositol phosphatase
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taining inositol phosphatases (GIPs), SH2 domain contaning
inositol phosphatases or proline-rich domain containing inositol
phosphate phosphatases, respectively [2]. However, the recently
discovered PI phosphatase skeletal muscle and kidney enriched
inositol phosphatase (SKIP) has noobvious domains apart from
the type II phosphatase homology domain and a small mem-
brane ruﬄe targeting domain [3] and thus has to be classiﬁed as a
uniquely simple member of the type II phosphatase family [4].
Many members of the type II phosphatase family are impor-
tant mediators of cellular signalling or membrane traﬃc and
play an important role in human health [1,5]. In particular, the
gene product responsible for Lowe’s oculocerebrorenal syn-
drome (OCRL), a member of the GIP phosphatase class, comes
to mind [6]. The disease is caused by the loss of the catalytic
activity of the OCRL phosphatase, which cannot be compen-
sated by the other knownmember of the GIP class, the INPP5B
phosphatase in humans, although they share high homology in
the phosphatase and BCR-GAP domain [7]. The cellular func-
tion of OCRL and other type II phosphatases is determined by
the actual catalytic properties of the type II phosphatase domain
and by the localisation of the enzyme [8,9], the latter being de-
termined by the domains that are able to interact with proteins
and/or compartments such as the SH2, BCR-GAP and proline
rich domains [1]. Many of these type II phosphatases are subject
to alternative splicing in the regions of these targeting domains,
thus creating diﬀerently localised phosphatases with similar
substrate speciﬁcity. For example, synaptojanin2 is spliced in its
C-terminal proline rich domain, resulting in six diﬀerent splice
forms with unique cellular localisation, whereas synaptojanin1
splicing in the proline rich domain results in diﬀerential devel-
opmental expression levels [10,11]. While there is some evidence
concerning the importance of the targeting of phosphatases to-
wards their distinctive compartments [3,9,12,13], the substrate
speciﬁcity and catalytic properties of the corresponding phos-
phatase domains are still ill deﬁned. In particular, the enzymo-
logical properties towards some inositol lipid substrates of these
phosphatases are available for a few of these enzymes [4,14,15].
However, due to variations in the assay conditions employed the
available data are not suited for a comparative analysis.
Here, we will describe the comparative determination of the
enzymological properties of the phosphatase domains of theblished by Elsevier B.V. All rights reserved.
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INPP5B, and the full length SKIP phosphatase. All tested
phosphatases showed an ability to hydrolyse phosphatidylin-
ositol 4,5 bisphosphate (PtdIns-4,5-P2), but diﬀered substan-
tially in their ability to employ PtdIns-3,4,5-P3 or Ins-1,4,5-P3.
Diﬀerential sensitivities towards the head group and fatty acid
composition of the lipid substrates were observed suggesting
that the phosphatase domains fulﬁl a unique catalytic function
that cannot be fully compensated by other phosphatases.2. Methods
2.1. Bacterial expression of PI 5-phosphatase domains
The boundaries of the phosphatase domains of synaptojanin1 (rat;
S470-R962) and synaptojanin2 (human; D474-R959), OCRL (human;
V202-E618) and INPP5B (mouse; A305-A721) were modelled on the
full length SKIP phosphatase (human), which roughly resembles the
boundaries used recently for obtaining the crystal structure of this
domain [16]. The phosphatase domain constructs of the ﬁve diﬀerent
phosphoinositide 5-phosphatases were cloned into the pGEX-4T2 ex-
pression vector (Pharmacia). These plasmids were transfected into a
DH5a strain of Escherichia coli and the phosphoinositide 5-phospha-
tases were expressed while bacteria were induced with 100 lM
isopropyl-b-D-thiogalactopyranoside at 18 C overnight. The gluta-
thione S-transferase-fusion proteins were aﬃnity-puriﬁed using gluta-
thione sepharose 4B (Pharmacia) and eluted with 20 mM reduced
glutathione and 500 mM NaCl, pH 8. Several mg of proteins of suf-
ﬁcient purity were regularly obtained using the described method for
expression and puriﬁcation (data not shown).
2.2. Malachite green phosphate release assay
The enzyme activity of the PI 5-phosphatases was measured with a
well-established phosphate release assay using an acidic malachite
green dye [17]. These assays were performed in the presence of water-
soluble inositol phosphates or phosphoinositides, respectively. Lipid
substrates were dried down, resuspended in 1% octylglucoside (OG),
which had the least interference with the colorimetric phosphate re-
lease determination, and sonicated for 10 min. The buﬀer conditions
for all experiments were as followed: 200 mM Tris, pH 7.4, 50 ng/ll
BSA. The phosphatase reaction was initiated by adding the enzyme to
the substrates and samples were incubated at 30 C. In order to stop
the enzyme reaction, 0.7 volume of the acidic dye solution (2.3 mg/ml
malachite green in 3.6 M HCl and 17 mM ammonium molybdate) was
added. The mixture was allowed to develop for 20 min and OD625 was
measured.
2.3. Testing substrate speciﬁcity
To analyse the substrate speciﬁcity of all ﬁve phosphoinositide
5-phosphatases, we employed the above described phosphate release
assay using the following substrates; PtdIns-4,5-P2nat (Lipid Pro-
ducts, UK), PtdIns-4,5-P2dC16, L-a-D-myo-phosphatidylinositol 3,4,5-
triphosphate 3-O-phospho linked, D(+)-sn-1,2-di-O-hexadecanoylglyceryl
(PtdIns-3,4,5-P3dC16), PtdIns-3,5-P2dC16, PtdIns-4-PdC16, PtdIns-5-
PdC16, Ins-1,5-P2, Ins-1,4,5-P3 and Ins-1,3,4,5-P4 (Cell Signals). In
order to achieve an OD625 of approximately 0.5 for all 5-phospha-
tases using 50 lM PtdIns-4,5-P2dC16 diﬀerent enzyme concentra-
tions were employed, which allowed us to compare the diﬀerent
recombinant 5-phosphatases to each other as a percentage of the
PtdIns-4,5-P2 activity. All experiments were carried out in the
presence of 50 lM substrate (in the presence of 0.25% octylgluco-
side) at 30 C for 30 min and were repeated twice.
2.4. KM–VMax analysis
To analyse the enzymatic properties of the PI 5-phosphatases, we
established KM and VMax values for the natural and the synthetic
PtdIns-4,5-P2 and PtdIns-3,4,5-P3dC16 for all ﬁve proteins. The water
soluble Ins-1,4,5-P3 was only examined for OCRL, INPP5B and
synaptojanin1. SKIP and synaptojanin2 lack the ability to hydrolyse
this inositol. Furthermore, Ins-1,4,5-P3 was tested in the presence and
absence of octylglucoside. We detected that the detergent changed the
enzymatic properties, which made this additional approach necessary.Ascending concentrations up to 300 lM of sonicated lipid and inositol
phosphates, respectively, were pre-incubated at 30 C and the phos-
phate release assay was initiated by adding the PI 5-phosphatase. In
order to achieve linear assays, the conditions for these KM/VMax studies
were optimised in respect to time and enzyme concentration. OD625
values were plotted against substrate concentration and KM and VMax
values were calculated using GraphPad Prism software.3. Results
3.1. Substrate speciﬁcity of the type II phosphatase domains
In order to compare the substrate speciﬁcity of the diﬀerent
phosphatases, it was important to assess ﬁrst the substrates
that have signiﬁcant turnover. The catalytic domains of these
phosphatases, modelled on the boundaries of the shortest
member of the type II 5-phosphatase family (SKIP) [4], were
therefore, tested for their ability to employ the lipids in a mixed
micelle assay. As shown in Fig. 1, all tested phosphatase do-
mains were able to hydrolyse eﬃciently PtdIns-4,5-P2 and to a
lesser extent PtdIns-3,4,5-P3, whereas other inositol lipids and
phosphates are hydrolysed suﬃciently only by some of the
tested phosphatases only. All tested phosphatase domains were
unable to eﬃciently hydrolyse PtdIns-5-P or its corresponding
head group Ins-1,5-P2, suggesting a preference for bis-phos-
phorylated inositol lipids. Indeed, PtdIns-4,5-P2 (natural and/
or synthetic) seems to be the preferred substrate for all tested
type II phosphatases, since hydrolysis of any other phospho-
inositide lipid was in comparison with either of similar or
weaker strength. Interestingly, PtdIns-3,5-P2 is not a good
substrate to any phosphatase except OCRL, whereas syna-
ptojanin2 and SKIP did not show any signiﬁcant turnover of
the soluble inositol phosphates Ins-1,4,5-P3 and Ins-1,3,4,5-P4.
However, synaptojanin1 did possess suﬃcient activity towards
Ins-1,4,5-P3, but had much lower reactivity when exposed to
Ins-1,3,4,5-P4.3.2. Sensitivity of the type II phosphatases towards head group
phosphorylation, fatty acid composition and micelle
presentation
The substrate speciﬁcity assessment revealed that the closely
related phosphatase domains did have signiﬁcant turnover
towards PtdIns-4,5-P2 and PtdIns-3,4,5-P3 as well as Ins-1,4,5-P3
(Fig. 1). The enzymological parameters KM (substrate aﬃnity)
and VMax (catalytic turnover) for these substrates were there-
fore assessed (Table 1). Given that these phosphatases have
not been characterised in a comparative fashion with respect to
these parameters before, it is reassuring that the observed KM
values for PtdIns-4,5-P2 are roughly in agreement with earlier
investigations focussing on puriﬁed synaptojanin1 [15] or re-
combinant SKIP [4], respectively. Furthermore, the KM values
for Ins-1,4,5-P3 for INPP5B was also closely resembling earlier
observations [14], thus validating our enzymological charac-
terisation and design of phosphatase domains. The VMax val-
ues are not easily compared to any published data, since these
values rely ultimately on the purity (speciﬁc activity) of the
enzyme preparation, which will inevitably vary. However,
while it is meaningless to compare the turnover (VMax) of the
diﬀerent phosphatase domains for a given substrate, it is
possible to compare the relative turnover (VMax as percentage
of the PtdIns-4,5-P2dC16 activity) of the diﬀerent substrates
for a given phosphatase domain (see Table 1).
Fig. 1. Substrate speciﬁcity of recombinant catalytic domains of the PI 5-phosphatase. Phosphate release assays were carried out using 50 lM of the
following substrates: PtdIns-4,5-P2nat, PtdIns-4,5-P2dC16, PtdIns-3,4,5-P3dC16, PtdIns-3,5-P2dC16, PtdIns-4-Pnat, PtdIns-4-PdC16, PtdIns-5-
PdC16, Ins-1,5-P2, Ins-1,3,5-P3 and Ins-1,3,4,5-P4. Enzyme reactions were initiated by adding the protein and incubated at 30 C for 30 min. The
phosphatase activity is presented as a percentage of the observed PtdIns-4,5-P2 activity employing a synthetic dihexadecanoyl PtdIns-4,5-P2 (PtdIns-
4,5-P2dC16). All other synthetic inositol lipids employed contain the same fatty acid composition in order to focus on the inﬂuence of the head group
on the substrate speciﬁcity. However, for comparison a PtdIns-4,5-P2 (PtdIns-4,5-P2natural), which had been puriﬁed from mammalian brain tissue
and thus contained an fatty acid composition resembling the natural in vivo environment (i.e., unsaturated fatty acids), was employed as well. PtdIns-
4-PdC16 was used as a negative control. The results were presented as the means ± S.E. of triplicate determinations.
A.C. Schmid et al. / FEBS Letters 576 (2004) 9–13 11The comparative analysis of the KM and VMax values led to
some conclusion with respect to the sensitivity of each phos-
phatase domain towards the head group, fatty acid composi-
tion and micellar presentation. As summarised in Table 2 each
tested 5-phosphatase had quite distinct properties, which did
not correlate with the shared primary sequence homology.
All tested phosphatase domains showed a unique response
towards (i) fatty acid composition (PtdIns-4,5-P2dC16 vs
PtdIns-4,5-P2natural), (ii) head group phosphorylation
(PtdIns-4,5-P2dC16 vs PtdIns-3,4,5-P3dC16) and (iii) micellar
presentation (Ins-1,4,5-P3+OG vs Ins-1,4,5-P3-OG). With re-
gard to the latter, only the two GIPs and synaptojanin1 were
able to process signiﬁcant amounts of Ins-1,4,5-P3, preferably
without detergent micelles being present, but each phosphatase
responded to the micellar presentation in a diﬀerent fashion
(OCRL, change of KM and VMax; INPP5B, change of KM only;
synaptojanin1, change of VMax only). Similarly, the fatty acid
composition of the lipid substrate (presented as a mixed mi-
celle) is sensed by each phosphatase in a diﬀerent fashion
(OCRL, moderate change in VMax only; INPP5B, moderate
change in KM and VMax; Synaptojanin1 (Syn1), moderate
change in KM but a very strong change in VMax; Synaptojanin2
(Syn2), no change in either KM or VMax; SKIP, substantial
change in KM and VMax). This unique sensing of the phos-
phatase domains is also detectable for the head group phos-
phorylation, a feature that should result in changes in the
aﬃnity (KM) of the phosphatase towards its substrate. Indeed,
as expected all tested phosphatases responded with a signiﬁ-
cant change in the KM values. However, some phosphatases
(INPP5B, synaptojanin1 and SKIP) also responded by
changing the VMax values. In particular, the SKIP phosphatasehad a 50-fold lower VMax for PtdIns-3,4,5-P3 as compared to
PtdIns-4,5-P2, eﬀectively overriding the 5-fold increase in af-
ﬁnity (KM) and thus making this enzyme an eﬀective and
speciﬁc PtdIns-4,5-P2 5-phosphatase. However, it cannot be
excluded given SKIP decreases insulin-induced PtdIns(3,4,5)P3
intracellular levels and Akt phosphorylation, that upon plasma
membrane recruitment SKIP is a more eﬃcient PtdIns(3,4,5)P3
5-phosphatase in intact cells [21].4. Discussion
The here observed diﬀerences in the enzymological proper-
ties and sensitivities of the type II phosphatases (GIPs, SCIPs
and SKIP) demonstrated the uniqueness of these enzymes,
which will have a bearing on their biological function. For
example, the OCRL phosphatase is supposed to be a PtdIns-
4,5-P2 phosphatase, since the absence of its activity results in
higher PtdIns-4,5-P2 level in vivo [18]. However, knockouts in
mice failed to create a ‘‘Lowe syndrome’’ phenotype, and it has
been speculated that the other member of the GIP family,
INPP5B, may be able to rescue any loss of function due to
OCRL [7]. Our data presented here (Table 2) clearly show that
these two GIP phosphatases are distinct in their catalytic
properties and sensitivities. OCRL is a PtdIns-4,5-P2 5-phos-
phatase that senses the fatty acid composition as demonstrated
by a corresponding change in VMax. INPP5B on the other hand
is not sensing the fatty acid composition, since only moderate
or insigniﬁcant changes in KM and VMax are recorded.
Both GIPs prefer PtdIns-4,5-P2 to PtdIns-3,4,5-P3, albeit due
to diﬀerent mechanisms. OCRL has a better aﬃnity for
Table 1
Enzymological properties of the type II phosphatases
KM (lM) VMax (U/l) VMax (%) KM/VMax
OCRL
PtdIns-4,5-P2dC16 22 8 45 20 100 0.22
PtdIns-4,5-P2natural 23 4 167 20 371 0.06
PtdIns-3,4,5-P3dC16 139 62 46 20 102 1.36
Ins-1,4,5-P3+OG 143 59 13 6 29 4.93
Ins-1,4,5-P3-OG 34 9 88 12 196 0.17
INPP5B
PtdIns-4,5-P2dC16 135 61 91 24 100 1.35
PtdIns-4,5-P2natural 48 15 41 13 45 1.06
PtdIns-3,4,5-P3dC16 44 13 12 4 13 3.38
Ins-1,4,5-P3+OG 194 60 56 17 61 3.18
Ins-1,4,5-P3-OG 55 22 58 13 64 0.86
Syn1
PtdIns-4,5-P2dC16 27 7 31 3 100 0.27
PtdIns-4,5-P2natural 100 21 401 34 1294 0.08
PtdIns-3,4,5-P3dC16 123 28 83 40 267 0.46
Ins-1,4,5-P3+OG 157 43 9 5 29 5.4
Ins-1,4,5-P3-OG 141 30 43 5 139 1.01
Syn2
PtdIns-4,5-P2dC16 54 11 15 9 100 0.54
PtdIns-4,5-P2natural 90 34 34 16 226 0.4
PtdIns-3,4,5-P3dC16 113 36 21 4 140 0.81
SKIP
PtdIns-4,5-P2dC16 107 30 298 50 100 1.07
PtdIns-4,5-P2natural 23 11 55 11 18 1.28
PtdIns-3,4,5-P3dC16 21 10 5 2 2 10.5
Puriﬁed recombinant type II 5-phosphatases (phosphatase domains
only) were analysed with respect to their corresponding KM and VMax
values using the indicated substrates as described in Section 2. For
comparison the VMax value (given in U/l; U ¼ lmol/min) is also
shown as a percentage of the PtdIns-4,5-P2dC16 value, the substrate
all tested phosphatases preferred. The ratio KM/VMax is shown as an
indicator of the substrate preference (low values indicating a good
substrate).
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lipid substrate. The two enzymes are hydrolysing the soluble
inositol trisphosphate (in the presence of OG), but again show
quite distinct characteristics. OCRL has a better aﬃnity to-
wards PtdIns-4,5-P2 than to Ins-1,4,5-P3, whereas INPP5B
has similar aﬃnities for both substrates. Although it cannot be
excluded that other domains present in the full length phos-
phatases inﬂuence the observed substrate speciﬁcity, it is more
likely that these domains modulate the biological function,
rather than the catalytic activity, due to targeting to diﬀerentTable 2
Sensitivities of the type II phosphatases
Enzyme Fatty acid Head group
KM VMax KM VMax
OCRL NS 371 632 NS
INPP5B 36 45 33 13
Syn1 370 1294 456 267
Syn2 NS NS 209 NS
SKIP 21 18 20 2
The data presented in Table 1 were analysed with respect to sensitivity toward
head group phosphorylation (PtdIns-4,5-P2dC16 vs. PtdIns-3,4,5-P3dC16)
table indicates the signiﬁcant changes of the KM and/or VMax values as a perc
Ins-1,4,5-P3-OG (NS ¼ no signiﬁcant change). As synaptojanin2 and SKIP
concerning the sensitivity towards micellar presentation could be drawn (NA
on signiﬁcant changes in the KM/VMax ratio (‘‘PtdIns-4,5-P2’’ indicating simcompartments (membranes) and/or protein complexes (cyto-
skeleton). Therefore, the apparent functional overlap in vivo
between mouse Ocrl1 and Inpp5b [7] must be a reﬂection of a
complex crosstalk of the metabolic pathways in which these
two enzymes participate rather than a direct compensation for
the loss of phosphatase activity in OCRL patients by INPP5B.
The ability of OCRL to hydrolyse PtdIns-3,5-P2 is also of
interest in that this phosphoinositide is known to be involved
in golgi traﬃcking where the OCRL enzyme is located [19].
In a similar fashion, the two members of the SCIP family
reveal distinct enzymological properties and sensitivities.
Firstly, synaptojanin2 does not work well on soluble inositol
phosphates. In contrast, synaptojanin1, like OCRL, is able to
use Ins-1,4,5-P3, although the natural PtdIns-4,5-P2 is by far
the preferred substrate (Table 2). This ability to work on the
Ins-1,4,5-P3 does allow synaptojanin1 to exert control on the
corresponding calcium rises, which has been recently dem-
onstrated in chinese hamster ovary cells [20]. However, unlike
OCRL, synaptojanin1 is much more accommodating towards
PtdIns-3,4,5-P3, since the diﬀerence in the KM/VMax values is
less severe. This ability to hydrolyse PtdIns-3,4,5-P3 eﬃ-
ciently is in agreement with earlier observations [21]. Syna-
ptojanin2 is overall characterised by an indiﬀerence towards
head group phosphorylation and fatty acid composition
(moderate change in KM/VMax values) suggesting that syna-
ptojanin2 is a 5-phosphatase for higher phosphorylated ino-
sitol lipids only.
Finally, the substrate speciﬁcity of SKIP is quite unique,
since it is almost exclusively hydrolysing PtdIns-4,5-P2. SKIP
does not have any signiﬁcant activity towards the soluble ino-
sitol phosphates and is characterised by a distinctly low turn-
over for PtdIns-3,4,5-P3, a recently proposed substrate in vivo
[22]. However, the unique exclusiveness of SKIP is similar to
that of the S. cerevisiae gene product INP54 [23] suggesting that
both enzymes might govern similar cellular responses. In
summary, our data reveal that the closely related type II
phosphatases are very unique in their catalytic properties, im-
plying that their corresponding biological function is not only
determined by their regulatory domains and thus localisation,
but their intrinsic catalytic properties. Our data reveal as well
that these phosphatases possess unique sensitivities towards
fatty acid and head group composition of the lipid substrate.
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